Profile
Michel Kaczorek joined Synt:em SA in 1995 and currently serves as President.
He is a Director of CliniGenetics SA.
Michel Kaczorek active positions
| Companies | Position | Start |
|---|---|---|
Synt:em SA
 Synt:em SA Pharmaceuticals: MajorHealth Technology Synt:em SA researches and manufactures drugs for the treatment of pain and cancer. The company specializes in the discovery and development of Central Nervous System (CNS) medicines and novel therapeutics for the treatment diseases. It was founded in 1995 by Michel Kaczorek and Caroline Roussel and is headquartered in Nîmes, France. | Chief Executive Officer | 31/12/1994 |
CliniGenetics SA
 CliniGenetics SA Pharmaceuticals: MajorHealth Technology CliniGenetics SA discovers and develops novel therapeutics for the treatment of cardiovascular, cerebrovascular, and lower limb ischemic diseases. The firm identifies and develops new pathways and products for the treatment of vascular diseases. CliniGenetics was founded in 2000 and is headquartered in Nimes, France. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Synt:em SA
Synt:em SA Pharmaceuticals: MajorHealth Technology Synt:em SA researches and manufactures drugs for the treatment of pain and cancer. The company specializes in the discovery and development of Central Nervous System (CNS) medicines and novel therapeutics for the treatment diseases. It was founded in 1995 by Michel Kaczorek and Caroline Roussel and is headquartered in Nîmes, France. | Health Technology |
CliniGenetics SA
CliniGenetics SA Pharmaceuticals: MajorHealth Technology CliniGenetics SA discovers and develops novel therapeutics for the treatment of cardiovascular, cerebrovascular, and lower limb ischemic diseases. The firm identifies and develops new pathways and products for the treatment of vascular diseases. CliniGenetics was founded in 2000 and is headquartered in Nimes, France. | Health Technology |
- Stock Market
- Insiders
- Michel Kaczorek